One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Making Progress Along the Challenging Road of Drug Development for Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.
doi : 10.1200/JCO-24-02656
Volume 43(13) pgs. 1523-1615 May 1, 2025
Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer.
doi : 10.1200/JCO-24-02624
Geospatial Genomics: Operationalizing Multilevel Conceptual Frameworks of Cancer Health Outcomes to Account for Gene-Person-Place Relationships.
doi : 10.1200/JCO.24.00751
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
doi : 10.1200/JCO.24.00994
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
doi : 10.1200/JCO.24.01124
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
doi : 10.1200/JCO-24-01269
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.
doi : 10.1200/JCO.24.00648
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.
doi : 10.1200/JCO-25-00179
Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in ATM, CHEK2, or PALB2 .
doi : 10.1200/JCO-24-02442
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
doi : 10.1200/JCO-24-01730
Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
doi : 10.1200/JCO-24-02689
Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
doi : 10.1200/JCO-25-00028
Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results.
doi : 10.1200/JCO-24-02533
Reply to: Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results.
doi : 10.1200/JCO-25-00032
Erratum: Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
doi : 10.1200/JCO-25-00567
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
doi : 10.1200/JCO-25-00558
